Selected Recent Publications.

(Mulligan lab trainees are underlined)

1.      Maritan SM*, Lian EY*, Mulligan LM (2017). An efficient and flexible cell aggregation method for 3D-spheroid production. Journal of Visualized Experiments (121) e55544, doi:10.3791/55544.

2.      Lian EY, Maritan S, Cockburn JG, Kasaian K, Crupi MJF, Hurlbut D, Jones SJM, Wiseman SM, Mulligan LM (2017). Differential contributions of RET isoforms to medullary and papillary thyroid carcinoma. Endocrine Related Cancer. 24(1): 53-69 DOI:10.1530/ERC-16-0393.

3.      Mulligan LM (2017). Additive effects of gene regulatory variants in multifactorial disease. Journal of Public Health and Emergency. 1: 29. Epub March 15, 2017

4.      Mulligan LM (2016). Progress and potential impact of RET kinase targeting in cancer. Expert Review of Proteomics 13(7): 631-633.  DOI: 10.1080/14789450.2016.1205491

5.      Smith J, Read M, Hoffman J, Brown R, Bradshaw B, Campbell C, Cole T, Dieguez Navas J, Eatock F, Gundara J, Lian E, McMullan D, MacDonald F, Morgan N, Mulligan L, Morrison PJ, Robledo M, Simpson M, Smith V, Stewart S, Trembath R, Sidhu S, Togneri F, Vialard L, Wake NC, Wallis Y, Watkinson JC, Maher ER, McCabe C, and Woodward ER (2016). Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression. Human Molecular Genetics. 25: 1836-1845. DOI: 10.1093/hmg/ddw057.

6.      Wang A, Ramjeesingh R, Chen C-H, Hurlbut D, Hammad N, Mulligan LM, Nicol C, Feilotter HE, and Davey S (2016). Reduction in membranous immunohistochemical staining of EpCAM-ICD correlates with poor patient putcome in primary colorectal adenocarcinoma. Current Oncology. 23(3): e171-e178. DOI: 10.3747/co.23.3028.

7.      Crupi MJF, Yoganathan P, Bone LN, Lian E, Fetz A, Antonescu CN, Mulligan LM (2015). Distinct temporal regulation of RET isoform internalization: roles of clathrin and AP2. Traffic 16: 1155-1173. DOI: 10.1111/tra.12315 

8.      Crupi MJF, Richardson DS, Mulligan LM (2015). Cell-surface biotinylation of receptor tyrosine kinases to investigate intracellular trafficking. In: Methods and Receptor Tyrosine Kinases: Protocols Ed. Germano, S. Springer Science, New York, USA Methods in Molecular Biology 1233: 91-102. DOI: 10.1007/978-1-4939-1789-1_9

9.      Mulligan LM (2014). RET revisited: expanding the oncogenic portfolio. Nature Reviews Cancer 14(3): 173-185.

10.  Hyndman BD*, Gujral TS*, Krieger JR, Cockburn JG, Mulligan LM (2013). Multiple functional effects of RET kinase domain sequence variants in Hirschsprung disease. Human Mutation. 34 (1): 132-142.

11.  Richardson DS, Rodrigues DM, Hyndman BD, Crupi MJF, Nicolescu AC, Mulligan LM (2012).  Alternative splicing results in RET isoforms with distinct trafficking properties. Molecular Biology of the Cell. 23 (19): 3838-3850.

12.  Cockburn JG, Richardson DS, Mulligan LM (2010). RET-mediated cell-migration and adhesion require multiple integrin subunits. Journal of Clinical Endocrinology & Metabolism 95 (11): E342-E346.

13.  Richardson DS, Mulligan LM (2010). Surface biotinylation for the visualization of internalization and recycling of membrane proteins. Journal of Fluorescence 20 (1): 401-405.

14.  Toledo RA, Wagner SM, Coutinho FL, Lourenço DM, Arantes J, Rocha MP, Reis MTA, Pellucci LA, Longuini VC, Lucon AM, Tavares MR, Villares MCVB, Pereira AA, Dahia PL, Mulligan LM, Toledo SPA (2010). High penetrance of pheochromocytoma associated with the novel C634Y-Y791F double germline mutation in the RET protooncogene. Journal of Clinical Endocrinology & Metabolism. 95 (3): 1318-1327.

15.  Hickey JG, Myers SM, Tian X, Zhu SJ, Shaw JLV, Andrew SD, Richardson DS, Brettschneider J, Mulligan LM (2009).  RET-mediated gene expression pattern is affected by isoform but not oncogenic mutation. Genes Chromosomes and Cancer 48: 429-440.

16.  Richardson DS, Gujral TS, Peng S, Asa SL, Mulligan LM (2009). Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins. Cancer Research 69 (11): 4861-4869.

*These authors contributed equally to this work.